A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Nemtabrutinib(drug)

Enrollment

1200 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2032

Study locations (30)

• USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama, United States
• Banner MD Anderson Cancer Center ( Site 0059), Gilbert, Arizona, United States
• Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051), Phoenix, Arizona, United States
• Arizona Oncology Associates - NAHOA ( Site 8007), Prescott, Arizona, United States
• Alta Bates Summit Medical Center ( Site 0004), Berkeley, California, United States
• Moores Cancer Center ( Site 0003), La Jolla, California, United States
• Care Access - South Pasadena ( Site 0070), Pasadena, California, United States
• Saint Joseph Hospital ( Site 0026), Denver, Colorado, United States
• Lutheran Medical Center ( Site 0027), Golden, Colorado, United States
• Intermountain Health St. Mary's Regional Hospital ( Site 0025), Grand Junction, Colorado, United States
• Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich, Connecticut, United States
• Clermont Oncology Center ( Site 0046), Clermont, Florida, United States
• Florida Cancer Specialists - South ( Site 7001), Fort Myers, Florida, United States
• Florida Cancer Specialists - East ( Site 7002), West Palm Beach, Florida, United States
• Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne, Indiana, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →